Yes, Amgen overpaid for Otezla—but that doesn't make it a mistake: analysts

Wall Street analysts have concluded Amgen's $13.4 billion purchase of psoriasis drug Otezla represents an overpayment of at least $2 billion. But with its Enbrel sales force, Amgen may be equipped to make the deal a success, they add.